drugset / Trial / NCT00528372

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372

Phase 3 Completed 1067 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. The safety of this treatment will also be studied.

Timeline

Start
2007-09
Primary completion
2009-02
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 2.5 mg Oral
Subject Dapagliflozin Small molecule 5 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral
Background Metformin Small molecule 500 mg Oral
Background Metformin Small molecule 2000 mg Oral